- Conditions
- Cataracts, Corneal Edema, Retinal Structural Change, Deposit and Degeneration, Visual Acuity Reduced Transiently
- Interventions
- Difluprednate ophthalmic emulsion 0.05%, Prednisolone acetate 1%
- Drug
- Lead sponsor
- Edward J. Holland
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- Edgewood, Kentucky • Lynbrook, New York • Mt. Pleasant, South Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–13
of 13
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Inflammation
- Interventions
- Difluprednate, Placebo
- Drug · Other
- Lead sponsor
- Sirion Therapeutics, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Fort Myers, Florida
- Conditions
- Cataracts, Inflammation
- Interventions
- Difluprednate ophthalmic emulsion, 0.05%, Prednisolone acetate ophthalmic suspension, 1.0%
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- Up to 3 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Herpes Simplex Virus Keratitis
- Interventions
- oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily, oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 100 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Uveitis
- Interventions
- Difluprednate, Prednisolone Acetate
- Drug
- Lead sponsor
- Sirion Therapeutics, Inc.
- Industry
- Eligibility
- 2 Years and older
- U.S. locations
- 1
- States / cities
- New Albany, Indiana
- Conditions
- Cataract
- Interventions
- Dextenza 0.4mg intracanalicular Insert, Durezol 0.05% Ophthalmic Emulsion
- Drug
- Lead sponsor
- Cathleen McCabe MD
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Bradenton, Florida
- Conditions
- Keratitis Bacterial
- Interventions
- Moxifloxacin Ophthalmic, Difluprednate Ophthalmic, Riboflavin Ophthalmic, Topical Placebo
- Drug · Other
- Lead sponsor
- Thomas M. Lietman
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- San Francisco, California • Miami, Florida
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- VV-14295
- Genetic
- Lead sponsor
- Kriya Therapeutics, Inc.
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Erie, Pennsylvania
- Conditions
- Inflammation
- Interventions
- Difluprednate, Placebo
- Drug
- Lead sponsor
- Sirion Therapeutics, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 219 participants
- U.S. locations
- 1
- States / cities
- Washington, Missouri
- Conditions
- Inflammation
- Interventions
- Difluprednate, Placebo
- Drug
- Lead sponsor
- Sirion Therapeutics, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 219 participants
- U.S. locations
- 1
- States / cities
- Washington, Missouri
- Conditions
- Inflammation
- Interventions
- Difluprednate, Placebo
- Drug · Other
- Lead sponsor
- Sirion Therapeutics, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Dry Eye Disease
- Interventions
- Difluprednate 0.05% ophthalmic emulsion, Difluprednate vehicle
- Drug · Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 722 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Endogenous Anterior Uveitis
- Interventions
- Difluprednate 0.05% ophthalmic emulsion, Prednisolone acetate 1.0% ophthalmic suspension
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas